Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

New Vaccine Blocks COVID-19 and Variants, Plus Other Coronaviruses

Study in animals identifies a potential way to build vaccines to fight future pandemics By Sarah Avery A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting…

Read More

Sparta Biomedical Receives FDA Breakthrough Device Designation for Biomimetic Implant

NEWS PROVIDED BY Sparta Biopharma, Inc.  DURHAM, N.C., March 17, 2021 /PRNewswire/ — Sparta Biomedical Inc., a developer of orthopedic solutions, today announced that its SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the…

Read More

Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO

DURHAM, NC, January 10, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PVSRIPO for the treatment of advanced…

Read More

Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial

Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS), and No Grade ≥ 3 Neurotoxicity (ICANS) PBCAR0191 Demonstrated Longest Durability of Response to 11 months in B-ALL PBCAR0191 with Enhanced Lymphodepletion Resulted in Objective Response Rate (ORR) of 83% (5/6)…

Read More

Istari Oncology Presents Positive Data from Phase 1 Study

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Data suggest that PVSRIPO, either…

Read More

Precision and SpringWorks Announce Clinical Collaboration

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase…

Read More

Newly published data shows positive results in KRYSTEXXA trial

MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate — Data adds to growing body of evidence on immunomodulation with KRYSTEXXA and emerging…

Read More

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies

Sept. 1, 2020 12:05 UTC Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM ~25-35 % survival over 5 years from diagnosis in vaccinated…

Read More

Grid Therapeutics Announces Enrollment of 1st Patient in Phase 1 Study

Grid Therapeutics, LLC, a clinical-stage biotechnology company developing a first-in-class, novel, human-derived targeted immunotherapy for solid tumors, today announced that the first patient has been dosed in a Phase 1/2 study of GT103 in patients with…

Read More